PNOE's self-administered metabolic mask brings lab-grade breath analysis to consumers
The portable device measures 23 biomarkers to provide personalized fitness and nutrition insights.
1Disruptive self-service design
PNOE's 2.0 mask eliminates the need for trained operators, enabling 8-minute self-administered tests in gyms or pharmacies. The redesign by Milan's Design Group Italia features detachable electronics for hygienic shared use while maintaining clinical-grade accuracy. This addresses key adoption barriers of traditional metabolic carts that require specialized lab settings and staff.
2Comprehensive biomarker tracking
The device measures 23 biomarkers including VO₂ max, resting metabolic rate, and metabolic flexibility - metrics blood tests can't provide. These data points help users optimize nutrition and training regimens. PNOE positions these insights between smartwatch estimates and full clinical workups, targeting the growing longevity and wellness markets.
3Scientific legacy meets accessibility
While metabolic breath analysis dates back a century, PNOE miniaturizes lab equipment into portable form. The technology stems from CEO Atsalakis' Cambridge PhD work on wearable sensors. The company maintains the gold standard accuracy of hospital-grade systems while making testing available outside elite athlete programs.
4Business model innovation
PNOE operates a B2B subscription model ($400-$1000/month) serving Equinox, Four Seasons, and NBA teams. The package includes hardware, software, and marketing support. Businesses use the tests during customer onboarding, linking results to tailored service recommendations - creating a wellness ecosystem around the data.
5Regulatory positioning
The device avoids medical claims, positioning as a wellness tool like scales rather than diagnostic equipment. While future applications may include disease detection, CEO Atsalakis acknowledges regulatory approval for such uses remains years away. This cautious approach enables faster market entry while building data for potential FDA submissions.
6Market expansion strategy
With 85% of revenue from the US, PNOE is expanding to Europe and through partners in Asia/Latin America. The company recently turned profitable with 100%+ annual growth. A planned Series B round will fund further distribution as VO₂ max tracking gains popularity among longevity-focused consumers.
7Competitive landscape
PNOE competes with Apple/Garmin's heart-rate-based VO₂ estimates and devices like Lumen's breath analysis. However, it claims superior accuracy to consumer wearables while being more accessible than hospital metabolic carts. The $22M-funded startup must balance clinical credibility with mass-market appeal in this emerging space.
8Industry implications
PNOE's success signals demand for professional-grade health tools in consumer settings. Its business model demonstrates how medical technologies can bridge into wellness markets. As metabolic health gains mainstream attention, such devices may redefine preventive care and personalized fitness programming beyond elite athlete applications.